A reliable measurement, a biological explanation and a useful treatment decision each need evidence. This map helps readers identify which part of a claim has actually been tested.
A useful reading framework follows the observation through its interpretation, mechanism, intervention and patient outcome. These are questions to examine, not a mandatory experimental sequence. An accurate assay can measure a marker that does not predict treatment benefit; a compound can bind a protein without proving that its effect depends on that protein. A model can reproduce an experiment without predicting an outcome in people. Each linked concept identifies a different evidence boundary and the source supporting it.
Shares Growth arrest, cell number and cell death, Growth-rate correction in drug-response assays, Context of use for a tumor model, Experimental and clinical drug exposure.
Shares Transporting trial evidence to another population, Biomarker cutoff selection and validation, Context of use for a tumor model, Analytical versus clinical validation.
Shares Transporting trial evidence to another population, Prognostic and predictive biomarkers.
Shares Growth arrest, cell number and cell death, Context of use for a tumor model.
Shares Competing events and cumulative incidence, Target-trial emulation.
Shares Decision curves and net benefit, Analytical versus clinical validation.
Shares Test agreement and diagnostic accuracy, Detection and quantification limits.
Shares Decision curves and net benefit, Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/